Board of Directors
Executive Chairman:
Professor Jesper Zeuthen:
Jesper Zeuthen was previously the managing director of the management company BI Technology A/S within the BankInvest Group, seven different venture funds focusing on biotech drug development raised in the period 1998-2006 and with more than 30 portfolio companies in Europe and in the USA. He was previously Head of Research & development at Novo Nordisk and Head of Research at The Danish Cancer Society. Professor Zeuthen is Vice-Chairman of the Danish Biotechnology Research and Innovation Centre (BRIC) and of TopoTarget. He has previously been a member of the Board of Directors of Genmab A/S (Chairman), Borean Pharma A/S (Chairman), Santaris Pharma A/S (Chairman), Zymenex Holding A/S (Chairman), Liplasome Pharma A/S (Chairman), Fibrogen Europe Oy and BioVision A/S. Professor Zeuthen is the author of more than 200 publications on immunology, cell biology and molecular biology and is an adjunct professor of biotechnology at the University of Copenhagen.
Professor Mogens H. Claesson
Mogens H. Claesson received the degrees of M.D. and DMSc in 1966 and 1977 respectively, both from the University of Copenhagen. He is an expert in cellular and functional immunology and has to date published around 200 peers reviewed research papers, as well as scientific reviews and book chapters on these subjects. He has previously held positions at the Department of Medical Anatomy, The University of Copenhagen as an associated professor, and held post doc fellowships in Melbourne, Toronto and Berkeley. Today he is a full professor in immunology at the Medical Faculty, University of Copenhagen. He has been the official opponent at numerous Doctoral and Ph.D. theses. His research is focused on experimental and clinical studies in tumor immunology and inflammatory diseases. He is today the leader of a group of pre and post graduate research fellows and supervises medical students working within narrowly defined research areas.
Dina R. Asmussen
Ms. Dina R. Asmussen is DanDrit Biotech’s former chief executive officer. She holds a Master Sc. Economics from Copenhagen Business School. She has many years of experience working with investments in biotech companies and running a biotech fund for Danske Bank.
Ulrik Finnemann
Ulrik Finnemann has been chief executive at Hotel Marienlyst & Casino in North Zealand during 10 years. He has a background from the financial sector.